Tags: pfizer | earnings | sales | drugs

Pfizer Sales Way Off Mark as Company Pursues AstraZeneca

Monday, 05 May 2014 07:38 AM

Pfizer Inc. reported revenue well below Wall Street expectations on falling sales of generic medicines, underscoring its interest in pursuing a $106 billion bid for rival AstraZeneca to promote new business growth.

Pfizer said on Monday it hoped its sweetened offer for AstraZeneca, which was made on Friday, would help the British drugmaker "engage with Pfizer and enter into discussions relating to a possible combination of the two companies."

AstraZeneca quickly rejected the sweetened bid, saying it "substantially" undervalued the company.

Pfizer said total first-quarter revenue fell 9 percent to $11.35 billion, which was $730 million below Wall Street expectations.

The largest U.S. drugmaker earned $2.33 billion, or 36 cents per share, in the quarter. That compared with $2.75 billion, or 38 cents, in the year-earlier period, when the company reported gains from the transfer of product rights.

Excluding special items, Pfizer earned 57 cents per share.

Analysts, on average, expected 55 cents, according to Thomson Reuters I/B/E/S.

Pfizer still expects 2014 adjusted earnings of $2.20 to $2.30 per share, but said its full-year net forecast was no longer valid.

If the merger goes through, it would be the largest acquisition of a British company by a foreign business.

Pfizer first approached AstraZeneca in January with an offer that valued AstraZeneca at 46.61 pounds per share. It made its second spurned approach on April 26, with an offer valued at 50 pounds a share.

Under British takeover rules, Pfizer has until May 26 to announce a firm intention to make an offer or give up.

© 2018 Thomson/Reuters. All rights reserved.

1Like our page
Pfizer Inc., the biggest U.S. drugmaker, on Monday reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.Pfizer, which is trying to take over Britain's AstraZeneca Plc, earned $2.33 billion, or...
pfizer, earnings, sales, drugs
Monday, 05 May 2014 07:38 AM
Newsmax Media, Inc.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved